April 19, 2018 07:01 AM EDTUpdated 07:23 AM

Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M

John Carroll

Editor & Founder

Kleiner Perkins is joining the syndicate backing Penn spinout Tmunity, adding $35 million for the cell therapy cause and bringing its launch round to a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M

John Carroll

Editor & Founder

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Bristol Myers CEO signals dealmaking will be a top priority in 2025

Drugmakers see a substantial, but manageable, hit to business from tariffs. But the worst may lie ahead

Roche CEO warns that tariffs could impact dealmaking

Versant's latest biotech focuses on inflammatory diseases

Merck is ‘well-positioned’ on Keytruda ahead of threatened pharma tariffs, CEO says

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Klein­er Perkins’ Beth Sei­den­berg bumps Tmu­ni­ty’s cell ther­a­py round to a cool $135M

Editor & Founder

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Kleiner Perkins’ Beth Seidenberg bumps Tmunity’s cell therapy round to a cool $135M